2023
Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria
Ivanics T, Claasen M, Samstein B, Emond J, Fox A, Pomfret E, Pomposelli J, Tabrizian P, Florman S, Mehta N, Roberts J, Emamaullee J, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff K, Hoteit M, Heimbach J, Taner T, Liapakis A, Mulligan D, Sapisochin G, Halazun K, Group O. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria. Annals Of Surgery 2023, 279: 104-111. PMID: 37522174, DOI: 10.1097/sla.0000000000006049.Peer-Reviewed Original ResearchConceptsUniversity of California San FranciscoMilan criteriaDonor liver transplantationHepatocellular carcinomaOverall survivalLiver transplantationPosttransplantation survivalEvaluate long-term oncologic outcomesUniversity of California San Francisco criteriaLiving donor liver transplantationRecurrence-free survivalKaplan-Meier methodTransplant selection criteriaProportion of patientsAdult LDLT recipientsNorth American centersLong-term survivalLiver transplant waitlistCalifornia San FranciscoLDLT recipientsMulticenter cohortConsensus guidelinesTransplantationPatientsPosttransplantationPredicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning
Kucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning. Scientific Reports 2023, 13: 7579. PMID: 37165035, PMCID: PMC10172370, DOI: 10.1038/s41598-023-34439-7.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularHumansLiver NeoplasmsMachine LearningMagnetic Resonance ImagingNeoplasm Recurrence, LocalRetrospective Studies
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularContrast MediaDeep LearningHumansLiver NeoplasmsMagnetic Resonance ImagingRetrospective StudiesConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2020
Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesions
2016
The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond
Mulligan D. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to Toronto and beyond. Hepatology 2016, 64: 1853-1855. PMID: 27641833, DOI: 10.1002/hep.28841.Peer-Reviewed Original Research
2015
Liver allocation: Can we ever get it right and should we ever get it right?
Neuberger J, Mulligan D. Liver allocation: Can we ever get it right and should we ever get it right? Hepatology 2015, 61: 28-31. PMID: 25130673, DOI: 10.1002/hep.27359.Peer-Reviewed Original ResearchCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsLiver TransplantationMaleSeverity of Illness IndexWaiting Lists
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchMeSH KeywordsCadaverCarcinoma, HepatocellularFemaleHumansLiver TransplantationMaleMiddle AgedNeoplasm StagingSurvival AnalysisTime FactorsTissue DonorsUnited StatesWaiting ListsConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime periodLiver Transplantation in the MELD Era: A Single-Center Experience
Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases And Sciences 2006, 51: 1070-1078. PMID: 16865573, DOI: 10.1007/s10620-006-8011-1.Peer-Reviewed Original ResearchMeSH KeywordsArizonaCarcinoma, HepatocellularFemaleHepatitis CHumansLiver DiseasesLiver NeoplasmsLiver TransplantationMaleMedical RecordsMiddle AgedOutcome Assessment, Health CareResource AllocationRetrospective StudiesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTissue and Organ ProcurementWaiting ListsConceptsDeceased donor liver transplantationLiver transplantationTransplantation ratesEndstage Liver Disease (MELD) scoreImpact of MELDDonor liver transplantationLiver Disease scoreUnderlying liver diseaseSingle-center experienceHepatocellular carcinoma patientsHepatitis C virusNew allocation policyHCC candidatesMELD implementationNew MELDTimely transplantClinical deteriorationMELD eraCarcinoma patientsLiver diseaseHepatitis C virus groupC virusHCC patientsMayo ClinicDropout rate
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantationHepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation
Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation 2004, 78: 580-583. PMID: 15446318, DOI: 10.1097/01.tp.0000129797.30999.69.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHepatocellular carcinomaHCV/Liver transplantationVirus infectionChronic hepatitis C virus (HCV) infectionSurvival rateChronic HCV infectionOrthotopic liver transplantationOutcomes of patientsOrgan Sharing dataHCC recurrence rateOverall survival rateLower survival rateHCV groupLT patientsHCV infectionHCC recurrencePatient survivalRecurrence rateUnited NetworkMean agePotential contraindicationsHCC groupLiver transplantation for hepatocellular carcinoma: The MELD impact
Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez‐Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004, 10: 36-41. PMID: 14755775, DOI: 10.1002/lt.20012.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationNew allocation policyHCC candidatesPerson yearsIncidence rateHepatocellular carcinomaLiver transplantationUNOS databaseEnd-stage liver diseaseT2 hepatocellular carcinomaDonor liver transplantationDropout rateDate of implementationHepatic decompensationNew MELDClinical deteriorationMELD scoreLiver diseaseStage T1United NetworkOrgan SharingWaiting listSurvivalTransplantationCarcinoma